Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2000, p. 354-356, Vol. 38, No. 1
Division of Medical Microbiology, Department
of Pathology, The Johns Hopkins University School of Medicine,
Baltimore, Maryland,1 and SMDC Health
System, Duluth, Minnesota2
Received 26 July 1999/Returned for modification 28 August
1999/Accepted 16 October 1999
The agent of human granulocytic ehrlichiosis (HGE), Ehrlichia
phagocytophila, and Ehrlichia equi probably comprise
variants of a single Ehrlichia species now called the
Ehrlichia phagocytophila genogroup. These variants share a
unique 153-kDa protein antigen with ankyrin repeat motifs encoded by
the epank1 gene. The epank1 gene was
investigated as an improved target for PCR diagnosis of HGE compared
with the currently used 16S rRNA gene target. Primers for
epank1 flanking a region that spans part of the 5' ankyrin
repeat coding region and part of the unique 3' region were synthesized.
Blood samples from 31 patients with suspected HGE who were previously
tested by 16S rRNA gene (16S) PCR and indirect immunofluorescent
antibody test (IFA) were retrospectively tested with the
epank1 primers. Eleven patients were 16S PCR positive and
had a seroconversion detected by IFA (group A), 10 patients were 16S
PCR negative but had a seroconversion detected by IFA (group B), and 10 patients were 16S PCR negative and seronegative (group C). Ten of the
11 group A patients were epank1 PCR positive, all 10 of the
group B patients were epank1 PCR positive, and all of the
PCR-negative and seronegative patients (group C) were
epank1 PCR negative. The epank1 primers are
more sensitive than the previously used 16S rRNA gene primers and
therefore may be more useful in diagnostic testing for HGE.
Ehrlichia species are
obligate, intracellular pathogens belonging to the
Rickettsiaceae family that are agents of human and veterinary disease in regions throughout the United States and Europe
(5, 12). A newly emerging Ehrlichia species, the
agent of human granulocytic ehrlichiosis (HGE) has become more
frequently diagnosed in regions where Ixodes species tick
vectors are abundant (5, 12). Human infection with the HGE
agent causes a nonspecific, influenza-like illness that can be
difficult to diagnose. Specific etiologic diagnostic tests for HGE
include blood smear examination for ehrlichial morulae within
neutrophils, PCR with primers based upon the HGE agent 16S rDNA
sequence (4, 7), indirect immunofluorescent antibody test
(IFA), which detects HGE agent antibodies in patient sera
(6), and direct cultivation of the HGE agent from patient blood (8). PCR is a highly useful diagnostic test for HGE
since it provides early detection of infection at a time when
therapeutic decisions are being made and since there are limitations
associated with the other diagnostic tests. Although PCR diagnosis of
HGE with the 16S rDNA primers GE9f and GE10r was shown to be highly sensitive (86%) and specific (100%) in a prospective evaluation (7), recent studies have shown a disappointing lack of
sensitivity in actual clinical practice (9). Thus, an
enhanced PCR method with increased sensitivity for the diagnosis of HGE
would be advantageous.
Phylogenetic studies indicate that the HGE agent belongs within a
narrow clade including Ehrlichia phagocytophila and
Ehrlichia equi (12). The close genetic
relationship between these species along with other molecular and
biological evidence suggests that they may actually be a single
Ehrlichia species that causes granulocytic ehrlichiosis in
both humans and animals. Recently, it has been discovered that these
Ehrlichia species share a unique gene, epank1, coding for a 153-kDa protein antigen, Epank1, which contains 11 ankyrin
repeats of 33 amino acids (11; P. Caturegli, K. M. Asanovich, J. J. Walls, J. S. Bakken, J. E. Madigan,
V. L. Popov, and J. S. Dumler, submitted for publication).
Recent evidence suggests that the HGE agent contains at least two
copies of epank1 in its genome (Caturegli et al.,
submitted). Considering this evidence, along with the uniqueness of
epank1 to the E. phagocytophila genogroup and the
fact that the 16S rRNA and groESL genes are highly conserved among prokaryotes, we investigated whether the PCR diagnosis of HGE
could be improved by the use of epank1 primers.
(This work was presented in part at the European Working Group-American
Society for Rickettsiology Joint Meeting, Marseilles, France, June
1999, abstr. 174.)
Patient specimens.
A total of 31 blood samples from patients
with suspected HGE agent infection were tested with the
epank1 primers. All patient whole-blood samples were
previously tested for HGE agent DNA in a PCR assay with the GE9f and
GE10r primers (4), and sera were tested for HGE agent
antibodies by IFA (2, 6, 10, 13). To exclude false-positive
IFA results due to cross-reactivity, patient sera were also tested for
Ehrlichia chaffeensis antibodies. Patients were initially
evaluated for HGE based upon typical history, clinical, and laboratory
findings that included at least some of the following: fever, headache,
malaise, myalgia, leukopenia, thrombocytopenia, anemia, elevated serum
hepatic transaminases, a history of tick bites or exposure to
tick-infected areas, and an illness occurring during a period of active
tick feeding. Twenty-four of the patients were from southeastern New
York, 7 were from either Minnesota or Wisconsin, and 1 was from the
Eastern Shore of Maryland. Twelve patients were PCR positive with the
HGE agent 16S rRNA gene primers and had a seroconversion detected by
IFA (group A). Ten of the patients were previously PCR negative but had
a seroconversion detected by IFA (group B). The remaining 10 patients
were previously PCR negative and seronegative (group C); 5 of these
patients were diagnosed with Lyme disease, 1 had an influenza-like
illness after a tick bite and persistent (>3 months) thrombocytopenia
suggestive of idiopathic thrombocytopenic purpura, and another had a
self-limited influenza-like illness with no hematologic abnormalities;
final etiologic diagnoses were never established for the remaining 3 subjects.
epank1 PCR.
DNA was extracted from 300 ml of
acute-phase, EDTA-anticoagulated whole blood with the Puregene kit
(Gentra Systems, Research Triangle Park, N.C.) and quantitated with a
GeneQuant UV spectrophotometer (Pharmacia Biotech, Piscataway, N.J.).
Two milligrams of DNA was added to a 100-µl PCR mixture containing
(final concentrations) 0.3 mM concentrations of the epank1
primers, 1.5 mM MgCl2, 0.6 mM deoxynucleoside
triphosphates, and 2 µl of eLONGase enzyme mixture (GIBCO/BRL,
Gaithersburg, Md.). The forward primer (LA6, 5'-GAGAGATGCTTATGGTAAGAC-3') and the reverse primer (LA1,
5'-CGTTCAGCCATCATTGTGAC-3') were designed to flank a region
of epank1 encoding 4 of the 11 ankyrin repeats, a region
comprising 444 nucleotides. Each PCR mixture included a known HGE agent
positive control (E. equi-infected horse neutrophil DNA) and
two negative controls (water blank and known negative human DNA).
Thermocycling was performed with preamplification denaturation for 2 min at 94°C, followed by 8 cycles of 30 s at 94°C and 30 s at 72°C; the annealing temperature during these 8 cycles was
lowered 2°C every 2 cycles from 62 to 56°C. Thereafter, amplification was performed for an additional 28 cycles at a constant denaturation temperature of 94°C for 30 s, annealing temperature of 54°C for 30 s, and extension temperature of 72°C for
30 s, followed by a final extension at 72°C for 5 min. The
resulting amplification yielded an approximately 444-bp product that
was visualized by ethidium bromide staining and 0.9% agarose gel
electrophoresis on an Eagle Eye UV gel imaging system (Stratagene, La
Jolla, Calif.).
Determination of analytical sensitivity.
A phagemid that
contains the epank1 gene truncated by 90 nucleotides on the
5' end was obtained by screening an E. equi lambda phage
Express (Stratagene) genomic library with polyclonal antiserum to
E. equi, followed by in vivo excision of the phagemid
containing the recombinant insert (Caturegli et al., submitted). The
identity of the ehrlichial gene was established by sequence analysis
(Caturegli et al., submitted). epank1-containing phagemids
were serially diluted from 107 to 100 copies/50
ml of PCR mixture to assess the analytical sensitivity of the
epank1 primers in a PCR assay. Additionally, known
quantities of HGE agent-infected tissue culture cells were diluted in
whole EDTA-anticoagulated blood from a healthy donor, and the extracted DNA was used in a PCR assay.
Analytical sensitivity.
As shown in Fig.
1, epank1 primers detected as
few as 10 plasmid copies and also detected ehrlichial DNA in samples
containing less than one infected cell per milliliter.
0095-1137/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Improved Sensitivity of PCR for Diagnosis of Human
Granulocytic Ehrlichiosis Using epank1 Genes of
Ehrlichia phagocytophila-Group Ehrlichiae
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (86K):
[in a new window]
FIG. 1.
Analytical sensitivity of epank1 PCR
determined with purified epank1 genes (A) and human blood
supplemented with various numbers of HGE agent-infected HL60 cells (B).
(A) The PCR master mixture was directly supplemented with between
100 and 107 plasmids containing the
epank1 gene or no plasmid (0). (B) Comparison of
epank1 PCR (top) and 16S rRNA gene PCR (bottom) performed
with nucleic acid templates prepared from human blood supplemented with
between 10
2 and 104 HGE agent-infected HL60
cells. The size of the amplified nucleotide fragment is designated on
the right of each panel; +C, genomic HGE agent control DNA prepared
from heavily infected HL60 cells; H2O, water only
control.
PCR.
As shown in Table 1, 10 of
the 11 (91%) group A HGE patients who were previously PCR positive
with the HGE agent 16S rRNA gene primers were also PCR positive with
the epank1 primers. From group B, all 10 (100%)
seropositive patients tested were epank1 PCR positive, and
from group C, none of the 10 former PCR-negative and seronegative
patients were PCR positive when tested with the epank1
primers. The intervals of illness and the mean geometric antibody
titers in convalescence were similar (P = 0.34 and
P = 0.80, respectively [Student's t
test]) for both groups of HGE patients regardless of 16S rRNA or
epank1 PCR results.
|
| |
DISCUSSION |
|---|
|
|
|---|
All diagnostic tests for HGE have limitations; cultivation of the organism may be difficult and is not timely (9), detection of morulae within a blood smear is not very sensitive (1, 2, 9), and the different antigens used for IFA may give discrepant or ambiguous results (9, 10, 13). PCR is the most useful diagnostic test for active disease, but the current methods need improvement owing to disappointing clinical sensitivity (9).
The sensitivity of detecting PCR-amplified HGE agent DNA in patient blood increased significantly when the epank1 primers were used. The epank1 primers amplified as few as 10 HGE agent epank1 genes. Additionally, epank1 primers amplified HGE agent DNA in an additional 10 patients who had been diagnosed with HGE by an IFA seroconversion but who were previously PCR negative with the HGE agent 16S rRNA gene primers. The amplification of HGE agent DNA with the epank1 primers for 91% of patients who were previously PCR positive with the HGE agent 16S rRNA gene primers also affirms a high PCR sensitivity. The exact explanation for increased sensitivity is not known but may be the result of targeting a multicopy gene.
The specificity of PCR with the epank1 primers is additionally high. In a previous study, only antibodies reactive with the E. phagocytophila genogroup reacted with the recombinant Epank1 protein, indicating that this protein antigen is unique to this group (Caturegli et al., submitted); correspondingly, only DNA from isolates of the E. phagocytophila genogroup could be amplified by PCR with the epank1 primers. Sequence analysis of the amplified region of epank1 revealed nucleic acid sequences of E. equi and HGE agent isolates that were nearly identical. Additionally, epank1 primers did not amplify HGE agent DNA from any of the patients who were previously HGE agent 16S PCR negative and seronegative. Therefore, specificity remained 100% when the epank1 primers were used for the PCR diagnosis of HGE, and the sensitivity increased to 95% compared with 48% with the 16S rRNA gene primers in the combined patient cohort.
Although the nucleic acid sequences in the PCR-amplified region of epank1 are nearly identical among the different E. equi and HGE agent isolates, some sequence variation is present among E. phagocytophila isolates (Caturegli et al., submitted). Sequence variation for epank1 between Swedish and Spanish E. phagocytophila strains was noted, and variation between the European E. phagocytophila strains and the North American strains is even greater. Amino acid sequence analysis of the Epank1 protein revealed similar variations among isolates. These variations among isolates and strains may explain why HGE agent DNA was amplified from the blood of one HGE patient from group A when alternate epank1 primers were used but not when the LA1 and LA6 epank1 primers were used (data not shown).
We have shown that PCR amplification of HGE agent DNA in infected patient blood with primers based upon epank1, which is unique for the E. phagocytophila group ehrlichiae, is both sensitive and specific. However, variation in epank1 sequences among strains may cause occasional false-negative results among North American patients. Regardless, the use of a genogroup-restricted gene with multiple copies in the genome as a target for PCR resulted in an improved clinical sensitivity with these archived blood samples. A pitfall of this strategy is the potentially larger degree of genetic heterogeneity in species- or group-restricted genes that may allow for decreases in sensitivity. It remains to be determined whether epank1 will be an appropriately sensitive target for PCR diagnosis in European patients with HGE. Further characterization of the heterogeneity in epank1 may reveal more-optimal regions that are conserved among the E. phagocytophila-group species for the design of primers to further improve the PCR diagnosis of HGE.
Currently, an optimal algorithm for laboratory confirmation of human ehrlichioses is not established. Definitive confirmation during active disease requires the use of PCR or culture. Two approaches for PCR confirmation include assays directed at specific etiologic agent identification and amplification of nucleic acids by using broad-range, "genus-specific" primers (2, 3, 7). Each approach is confounded by the potential for missed diagnoses and increased cost. Until issues of sensitivity, specificity, and cost regarding broad-range PCR for clinical applications are addressed, directed investigation using validated assays that identify specific etiologic agents is a proven approach.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grant RO1 AI41213-01 from the National Institutes of Allergy and Infectious Diseases.
The authors thank Maria Aguero-Rosenfeld and Donna McKenna for invaluable assistance in obtaining clinical data.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Medical Microbiology, Department of Pathology, The Johns Hopkins Medical Institutions, Meyer B1-193, 600 North Wolfe St., Baltimore, MD 21201. Phone: (410) 955-5077. Fax: (410) 614-8087. E-mail: sdumler{at}pathlan.path.jhu.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Aguero-Rosenfeld, M. E.,
H. W. Horowitz,
G. P. Wormser,
D. F. McKenna,
J. Nowakowski,
J. Munoz, and J. S. Dumler.
1996.
Human granulocytic ehrlichiosis: a case series from a single medical center in New York State.
Ann. Intern. Med.
125:904-908 |
| 2. |
Bakken, J. S.,
J. Krueth,
C. Wilson-Nordskog,
R. L. Tilden,
K. Asanovich, and J. S. Dumler.
1996.
Clinical and laboratory characteristics of human granulocytic ehrlichiosis.
JAMA
275:199-205 |
| 3. |
Buller, R. S.,
M. Arens,
S. P. Hmiel,
C. D. Paddock,
J. W. Sumner,
Y. Rikhisa,
A. Unver,
M. Gaudreault-Keener,
F. A. Manian,
A. M. Liddell,
N. Schmulewitz, and G. A. Storch.
1999.
Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis.
N. Engl. J. Med.
341:148-155 |
| 4. |
Chen, S.-M.,
J. S. Dumler,
J. S. Bakken, and D. H. Walker.
1994.
Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease.
J. Clin. Microbiol.
32:589-595 |
| 5. | Dumler, J. S., and J. S. Bakken. 1995. Ehrlichial diseases of humans: emerging tick-borne infections. Clin. Infect. Dis. 20:1102-1110[Medline]. |
| 6. | Dumler, J. S., K. M. Asanovich, J. S. Bakken, P. Richter, R. Kimsey, and J. E. Madigan. 1995. Serologic cross-reactions among Ehrlichia equi, Ehrlichia phagocytophila, and human granulocytic ehrlichia. J. Clin. Microbiol. 33:1098-1103[Abstract]. |
| 7. | Edelman, D. C., and J. S. Dumler. 1996. Evaluation of an improved PCR diagnostic assay for human granulocytic ehrlichiosis. Mol. Diagn. 1:41-49[CrossRef][Medline]. |
| 8. |
Goodman, J. L.,
C. Nelson,
V. Blaise,
J. E. Madigan,
J. S. Dumler,
T. J. Kurtti, and U. G. Munderloh.
1996.
Direct cultivation of the causative agent of human granulocytic ehrlichiosis.
N. Engl. J. Med.
334:209-215 |
| 9. | Horowitz, H. W., M. E. Aguero-Rosenfeld, D. F. McKenna, D. Holmgren, T.-C. Hsieh, S. A. Varde, J. S. Dumler, J. M. Wu, I. Schwartz, Y. Rikihisa, and G. P. Wormser. 1998. Clinical and laboratory spectrum of culture-proven human granulocytic ehrlichiosis: comparison with culture-negative cases. Clin. Infect. Dis. 27:1314-1317[Medline]. |
| 10. | Magnarelli, L. A., J. W. Ijdo, J. S. Dumler, R. Heimer, and E. Fikrig. 1998. Reactivity of human sera to different strains of granulocytic ehrlichiae in immunodiagnostic assays. J. Infect. Dis. 178:1835-1838[CrossRef][Medline]. |
| 11. |
Storey, J. R.,
L. A. Doros-Richert,
C. Gingrich-Baker,
K. Munroe,
T. N. Mather,
R. T. Coughlin,
G. A. Beltz, and C. I. Murphy.
1998.
Molecular cloning and sequencing of three granulocytic Ehrlichia genes encoding high-molecular-weight immunoreactive proteins.
Infect. Immun.
66:1356-1363 |
| 12. | Walker, D. H., and J. S. Dumler. 1996. Emergence of the ehrlichioses as human health problems. Emerg. Infect. Dis. 2:18-29[Medline]. |
| 13. | Walls, J. J., M. Aguero-Rosenfeld, J. S. Bakken, J. L. Goodman, D. Hossain, R. C. Johnson, and J. S. Dumler. Inter- and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test. J. Clin. Microbiol. 37:2968-2937. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»